• AMPLIFY-7P Phase 1 preliminary disease-free ("DFS") survival demonstrates strong correlation between T cell response and reduced risk of progression or death • AMPLIFY-7P Phase 1 data presented at ASCO demonstrated 100% of patients develop mKRAS-specific Tcell response with ~66% of responses including both CD4+ and CD8+ T cells • Long term follow up of the AMPLIFY-201 Phase 1 study will be terminated, and long term follow up of the AMPLIFY-7P Phase 1 study will be minimized to collect only overall surviva ...

BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio"))), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the pricing of an approximately $11.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof), and accompanying common warrants to purchase common stock, before deducting underwriting discounts ...

Elicio intends to use the net proceeds from this offering together with its existing cash, cash equivalents and marketable securities, for the advancement of its development pipeline, as well as for working capital and general corporate purposes. differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, market risks and uncertainties and the risk that the offering of its securities will not be consummated, and the satisfaction of customary ...

BOSTON, June 27, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that it has commenced an underwritten public offering of its shares of common stock and accompanying common warrants and, in lieu of its shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accomp ...

The AMPLIFY-7P study is evaluating the 7-peptide formulation, ELI-002 7P, in patients with mKRAS-driven solid tumors following standard locoregional treatment. Data were based on the May 24, 2024 data cutoff date of 14 patients with minimal residual disease who enrolled in the Phase 1 cohort of the AMPLIFY-7P study, with a median follow up for the DFS endpoint of 29.1 weeks: Christopher Haqq, M.D., Ph.D., Elicio's Executive Vice President, Head of Research and Development, and Chief Medical Officer, added, ...

About Elicio Therapeutics Cautionary Note on Forward-Looking Statements Investor Relations Contact Brian Piekos Elicio Therapeutics IR@elicio.com 857-209-0153 Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which ...

BOSTON, June 18, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on June 17, 2024, the Company granted an aggregate of 5,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement st ...

About Elicio Therapeutics Brian Piekos Elicio Therapeutics IR@elicio.com to be covered by the safe-harbor provisions of the PSLRA. Such forward-looking statements are based on our expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to, Elicio's plans to research, develop and commercialize its current and future product candidates. Investor Relations Contac ...

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, "Elicio Therapeutics" or "Elicio"), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced preliminary data from the ongoing AMPLIFY- 7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in a poster presentation at the American Society of Clinical Oncology ("ASCO") Annual Meeting, being held May 31-Ju ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-39990 (State or other jurisdiction of incorpora ...